Ekso Bionics Holdings, Inc. Q1 FY2025 Earnings Call

· Earnings call transcript and AI-powered summary

Financial Performance

  • Q1 2025 revenue was approximately $3.4 million, down from $3.8 million in Q1 2024. Management attributed this decline to capital budget constraints at inpatient rehabilitation facilities impacting Enterprise Health product sales.
  • Gross profit was about $1.8 million versus $2.0 million in Q1 2024. Gross margin improved to 54%, up from 52%, supported by supply chain cost savings and lower service expenses.
  • Operating expenses held relatively steady at $5.3 million compared to $5.2 million in the prior-year period.
  • Net loss narrowed to $2.9 million ($0.12 per share) from a $3.4 million loss ($0.20 per share) in Q1 2024.
  • Q1 2025 operating cash use was $2 million, significantly improved versus $3.5 million in Q1 2024.
  • Cash and restricted cash totaled $8.1 million as of March 31, 2025, up from $6.5 million at year-end 2024.

Operational and Commercial Highlights

  • Enterprise Health revenue softness stemmed from customer budget disruptions tied to macroeconomic uncertainty. However, Ekso Indego Personal showed “good growth.”
  • CMS pricing determination for Indego Personal (issued Q2 2024) continues to open access for Medicare beneficiaries with spinal cord injuries.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Greetings, and welcome to the Ekso Bionics First Quarter 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce to your host, Stephen Kilmer of Investor Relations. Thank you. You may begin. Stephen Kilmer: Thank you, operator, and good afternoon, everyone. Earlier today, Ekso Bionics released financial results for the first quarter ended March 31, 2025. A copy of the press release is available on our website. I would like to point out that management will make statements during this call that include forward-looking statements within the meaning of the federal securities, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements, including statements regarding our business strategy, future financial performance or operational expectations or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. Fo

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional